ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Merus NV

Merus NV (2GH)

42.20
0.80
(1.93%)
Closed 08 December 8:00AM
Realtime Data

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
42.20
Bid
41.80
Offer
42.80
Volume
0.00
0.00 Day's Range 0.00
21.40 52 Week Range 58.50
Previous Close
41.40
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
127
Financial Volume
-
VWAP
-

2GH Latest News

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing...

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia – Les données...

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit Petosemtamab bekannt

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1-2.3148148148143.2474319244.19451697DE
4-7.8-15.65051.540.411744.74603537DE
12-3-6.6371681415945.251.540.412747.17167127DE
26-6-12.448132780148.257.540.415948.57608533DE
5219.283.47826086962358.521.39999917344.34418355DE
15618.477.310924369723.858.51916742.00023485DE
26018.477.310924369723.858.51916742.00023485DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M
A6NAsana Inc
21.00 €
(43.84%)
19.08k
NL8Genesis Ai Corp
0.0214 €
(40.79%)
13.33k
RQ0DWave Quantum Inc
4.814 €
(34.92%)
1.15M
K8DWellfield Technologies Inc
0.0342 €
(34.65%)
30.8k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
M0YNMynaric AG
1.40 €
(-72.66%)
303.13k
W47Grid Battery Metals Inc
0.0115 €
(-39.47%)
7
47GAGo Metals Corp
0.0202 €
(-36.88%)
3.44k
4APApollo Minerals Ltd
0.0055 €
(-35.29%)
270.7k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
D7GNel ASA
0.2625 €
(-1.69%)
4.24M
LK1Lake Resources
0.029 €
(-6.75%)
2.32M
TUI1Tui AG
8.40 €
(1.11%)
2.17M
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M

Discussion

View Full Feed
surrealistrader surrealistrader 8 minutes ago
Clearly Steve Cyros tampers with his handheld XRF....

...and his same hairy hand on that sci-aps device showing bogus results somehow find their way into company disclosures and social media posts on the regular. It's hard to say that these guys have taken a turn at some point, becaus
SDRC
thistraderknowsall thistraderknowsall 9 minutes ago
SUKU flys to $1+ on the AI news!! We rich!!

They mentioned SUKU will do a FARM
run up!!! $68!!!!
Guzzi62 Guzzi62 25 minutes ago
From the article:

OUR PICKS FOR 2025

NWBO and SHPH Groundbreaking Cancer Treatment Combo
December 7, 2024|Revolutionary cancer treatment

1. Northwest Biotherapeutics' DCVax-L and Shuttle Pharmaceuticals' Ropidoxuridine show groundbreaking results
NWBO SHPH
Guzzi62 Guzzi62 28 minutes ago
Thanks JonnyShooter on Stocktwits.

https://kingofpennystock.com/f/nwbo-and-shph-groundbreaking-cancer-treatment-combo
NWBO
SilkRoad SilkRoad 34 minutes ago
The rate you are using to say they won’t make a metric ton for three years is not the rate at which they are operating at now especially when they say they expect to make 10,000 pounds of spider silk yarn in 2025 and Dr. Kumar said multi-tons of silk will be made in 2025. Note Kim said yarn, not co
KBLB
thistraderknowsall thistraderknowsall 39 minutes ago
SUKU Altcoin crypto flys $1 to $5+ on the AI news!! We rich!! #1Trending!!!!
SilkRoad SilkRoad 52 minutes ago
Well said mojo.
KBLB
SilkRoad SilkRoad 55 minutes ago
Thank you.
KBLB
JohnnyHydrogen JohnnyHydrogen 1 hour ago
US AI Task Force Co-Chair Asks FERC to Support Co-Located Data Centers - Letter

https://www.usnews.com/news/technology/articles/2024-12-06/us-ai-task-force-co-chair-asks-ferc-to-support-co-located-data-centers-letter

Seems like 'co-location' is going to be one of the bi
FCEL
littlejohn littlejohn 1 hour ago
...HODL...$6 billion in 3rd quarter, 2024

on the calendar, was 1st quarter,2025

for SMCI...

Gotta get the time setting understood

to follow SMCI better...

Estimate until quarterly filing is released...

...HODL.
SMCI
jog49 jog49 1 hour ago
Which one of the letters in LGBTQ+ represents Whalen? I believe I have seen that face before hanging around public restrooms. Sometimes there is a guy with him holding a cat. Just saying . . . . . . .
FNMA
lakers17 lakers17 1 hour ago
The problem is not your DD. Overall you do a lot of DD and most of it is solid. The problem is this is the OTC where anything can happen. The problem is your arrogance, bragging and insistence in your picks putting down others as many of your plays have collapsed because this is the Wild West OTC
AFFU
Lakota-45 Lakota-45 2 hours ago
Hey - 'BDEZ' - it's been a while.
You seem familiar to me, but I can't place it !!!

Regarding your comment about volume; That will come when Outdoorsmen, and
LikeRE announce that they are ready to Go Public, which, I think
. . . will be in the not-so-distant
WDLF
bar1080 bar1080 2 hours ago
Updated daily perhaps, but >90 days out of_date. Worthless. Weren't you talking that up a year or two ago? LOLOLOL
lakers17 lakers17 2 hours ago
Absolutely hilarious. You really have no clue do you? And claiming charts work on low trip stocks is just about a stupid as predicting .002 or higher on a .0001 stock. No chart does this. Period. So one year of 2024 OTC will be like 2021 and hundreds of posts saying that I guess bombed, as did
GRLT
jog49 jog49 2 hours ago
"Bill and John, they get it, and will reap great rewards"

Bill and John run hedge funds and may hold less shares personally than you do or some of the others here. Most everyone here that comments falls under the mom-and-pop investors umbrella.
FNMA
knrorrel knrorrel 2 hours ago
The trend is clear to everyone - just look at it here

https://www.stockscores.com/charts/charts/?ticker=smci
imho

SMCI
knrorrel knrorrel 2 hours ago
6 billion in sales in Q1 2025 WOW - wow, that would be a big increase from last year and POS only $50. That's not possible. The $SMCI can't be below $100 for long
all only imho

SMCI
wallstreet1231 wallstreet1231 2 hours ago
Poor fella doesn’t even realize he has already been diluted. Roughly one billion new shares were created in the recent reverse split. Stock is down over 50% since the reverse split.

Now he will tell you there isn’t any dilution since the company hasn’t issued/used any of the new sha
SNPW
powerbattles powerbattles 2 hours ago
New rule is good.
https://media.stocktwits-cdn.com/api/3/media/694045/default.jpeg
knrorrel knrorrel 2 hours ago
EPIC and AWESOME is = NO DILU !

THANK YOU
GVSI
knrorrel knrorrel 2 hours ago
NO DILU !
FORW
knrorrel knrorrel 2 hours ago
super SS 👍👍👍 https://www.otcmarkets.com/stock/FORW/security
FORW

Your Recent History

Delayed Upgrade Clock